Cerevel Therapeutics

About Cerevel Therapeutics

Cerevel Therapeutics (NASDAQ:CERE) focuses on the discovery and development of new therapies for neuroscience diseases. The company is dedicated to unraveling the mysteries of the brain to treat neurological disorders with precision and care, aiming to lead a new era in neuroscience. Cerevel's projects span a range of conditions, including schizophrenia, epilepsy, and Parkinson's disease, reflecting its deep commitment to improving the lives of patients battling these challenging disorders. Their objectives are clear: to push the frontiers of neuroscience, bring forth innovative treatments that can significantly improve patient outcomes, and navigate the complexities of brain disorders with groundbreaking research and development. Through unyielding commitment to science and patients, Cerevel Therapeutics strives to make a lasting impact in the field of neurological health.

What is Cerevel Therapeutics known for?

Snapshot

2018

Year founded

335

Employees

Massachusetts, United States

Head office

Loading Map...

Operations

All Locations

United States

Products and/or services of Cerevel Therapeutics

Tavapadon for Parkinson's disease, aimed at providing symptomatic relief and potentially slowing disease progression.
CVL-871, a D1/D5 partial agonist developed for treatment of dementia-related apathy.
Darigabat, targeting anxiety and epilepsy through modulation of the GABA-A receptor.
CVL-354, a KOR antagonist designed for major depressive disorder, exploring a new avenue for treatment.
Emraclidine, focused on improving cognitive and daily functioning in patients with schizophrenia.
CVL-231, an M4 selective agonist offering a novel approach for the treatment of schizophrenia.